Xencor, Inc. (XNCR) Stock Price

XNCRStock

$29.30+244.77%52W

Market Cap$2.18B

P/E—

PEG Ratio—

Div yield—

Beta0.88

XNCR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)144.44%

Price vs S&P 500 (4W)42.14%

VGM Score58.77

Book Value / Share (Quarterly)$6.77

P/TBV (Annual)1.74x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-8.63%

Cash Flow / Share (Quarterly)$-2.80

Price vs S&P 500 (YTD)77.43%

Net Profit Margin (TTM)-155.59%

EPS (TTM)$-2.17

10-Day Avg Trading Volume1.29M

EPS Excl Extra (TTM)$-2.17

Revenue Growth (5Y)0.46%

EPS (Annual)$-1.24

ROI (Annual)-12.17%

Net Profit Margin (5Y Avg)-73.27%

Cash / Share (Quarterly)$6.14

Revenue Growth QoQ (YoY)17.46%

ROA (Last FY)-10.50%

Revenue Growth TTM (YoY)-33.17%

EBITD / Share (TTM)$-2.79

ROE (5Y Avg)-13.05%

Operating Margin (TTM)-208.93%

Cash Flow / Share (Annual)$-1.92

P/B Ratio3.39x

P/B Ratio (Quarterly)2.37x

Net Income / Employee (Annual)$-353,600

EV / Revenue (TTM)16.81x

Net Interest Coverage (TTM)-5.50x

ROA (TTM)-20.38%

EV / EBITDA (TTM)29.03x

EPS Incl Extra (Annual)$-1.24

Current Ratio (Annual)6.25x

Quick Ratio (Quarterly)6.09x

3-Month Avg Trading Volume0.94M

52-Week Price Return244.77%

Revenue / Employee (TTM)$403,700

Tangible BV / Share (Quarterly)$6.68

P/S Ratio (Annual)13.57x

Asset Turnover (Annual)0.14x

52-Week High$29.42

Operating Margin (5Y Avg)-88.36%

EPS Excl Extra (Annual)$-1.24

CapEx CAGR (5Y)-25.55%

Tangible BV CAGR (5Y)2.42%

26-Week Price Return155.69%

Quick Ratio (Annual)6.02x

13-Week Price Return157.28%

Total Debt / Equity (Annual)0.19x

Current Ratio (Quarterly)6.39x

Enterprise Value$1.76B

Revenue / Share Growth (5Y)-4.64%

Asset Turnover (TTM)0.13x

Book Value / Share Growth (5Y)-2.20%

Revenue / Employee (Annual)$483,000

Pretax Margin (Annual)-71.38%

Cash / Share (Annual)$7.62

3-Month Return Std Dev66.62%

Net Income / Employee (TTM)$-628,200

ROE (Last FY)-14.46%

Net Interest Coverage (Annual)-1.51x

EPS Basic Excl Extra (Annual)$-1.24

P/FCF (TTM)9.50x

Receivables Turnover (TTM)2.34x

Total Debt / Equity (Quarterly)0.21x

EPS Incl Extra (TTM)$-2.17

Receivables Turnover (Annual)2.79x

ROI (TTM)-23.79%

P/S Ratio (TTM)16.24x

Pretax Margin (5Y Avg)-71.63%

Revenue / Share (Annual)$1.69

Tangible BV / Share (Annual)$8.73

Price vs S&P 500 (52W)226.46%

Year-to-Date Return89.39%

5-Day Price Return14.11%

EPS Normalized (Annual)$-1.24

ROA (5Y Avg)-9.08%

Net Profit Margin (Annual)-73.20%

Month-to-Date Return43.47%

Cash Flow / Share (TTM)$-1.81

EBITD / Share (Annual)$-2.37

Operating Margin (Annual)-148.65%

LT Debt / Equity (Annual)0.12x

ROI (5Y Avg)-10.36%

LT Debt / Equity (Quarterly)0.15x

EPS Basic Excl Extra (TTM)$-2.17

P/TBV (Quarterly)2.40x

P/B Ratio (Annual)1.72x

Pretax Margin (TTM)-153.23%

Book Value / Share (Annual)$8.84

Price vs S&P 500 (13W)154.48%

Beta0.88x

P/FCF (Annual)31.96x

Revenue / Share (TTM)$1.38

ROE (TTM)-28.66%

52-Week Low$7.50

vGradeC

gGradeD

mGradeA

vgmGradeC

XNCR Earnings Surprise History

Q2 25-0.41est. -0.71

Q3 25-0.08est. -0.70

Q4 25-0.09est. -0.58

Q1 26-1.71est. -0.75

Q2 26-0.29est. -0.82

XNCR Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.15

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
XNCRXencor, Inc.	C	D	A	$29.30
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Xencor, Inc.

Xencor Inc is a clinical-stage biopharmaceutical company developing engineered antibody therapeutics for cancer and autoimmune diseases. The company leverages its proprietary XmAb technology platform to advance a pipeline of antibody candidates through clinical development. Xencor generates revenue through collaboration and licensing agreements with larger pharmaceutical partners, reducing development risk while advancing its research programs.